Comparative Pharmacology
Head-to-head clinical analysis: ALOGLIPTIN versus SITAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOGLIPTIN versus SITAGLIPTIN.
ALOGLIPTIN vs SITAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
25 mg orally once daily
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Clinical Note
moderateSitagliptin + Gatifloxacin
"Sitagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateAlogliptin + Gatifloxacin
"Alogliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSitagliptin + Rosoxacin
"Sitagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateAlogliptin + Rosoxacin
"Alogliptin may increase the hypoglycemic activities of Rosoxacin."
12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor